BostonGene is collaborating with the SWOG Cancer Research Network on the PRISM Phase II trial for extensive-stage small cell lung cancer (ES-SCLC). The study will utilize BostonGene’s machine learning-driven multiomic platform to identify molecular subtypes and SLFN11 status, assigning maintenance therapies including durvalumab or investigational agents such as PARP inhibitors. Up to 900 patients will be enrolled, with outcomes measured against biomarker-driven targeted therapy strategies.